Press Release

Europe Digital Therapeutics Market to Grow with a CAGR of 12.43% through 2030

Technological advancements and innovation and increased adoption of remote patient monitoring is expected to drive the Europe Digital Therapeutics Market growth in the forecast period, 2026-2030.


According to TechSci Research report, “Europe Digital Therapeutics Market - By Country, Competition, Forecast and Opportunities, 2030F”, the Europe Digital Therapeutics Market stood at USD 1.94 Billion in 2024 and is expected to reach USD 3.93 Billion by 2030 with a CAGR of 12.43% during the forecast period.

The Europe Digital Therapeutics Market is experiencing rapid growth, driven by a combination of technological advancements, an aging population, and the rising prevalence of chronic diseases. Digital therapeutics (DTx), which offer evidence-based interventions through software applications and digital platforms, are transforming the way healthcare is delivered across the region. These solutions are designed to manage, treat, and prevent various medical conditions, such as diabetes, cardiovascular diseases, mental health disorders, and neurological conditions, offering patients more accessible, cost-effective, and personalized care. As the healthcare landscape in Europe evolves, digital therapeutics are becoming an integral part of treatment regimens, particularly in managing long-term and complex conditions that require continuous monitoring and management.

A key driver of the market’s growth is the increasing demand for personalized, patient-centric healthcare. As healthcare systems across Europe face mounting pressure to address the growing burden of chronic diseases, digital therapeutics are offering an effective solution to reduce the strain on traditional healthcare services. These solutions enable real-time monitoring of patients’ health conditions, such as blood glucose levels for diabetics or heart rate for individuals with cardiovascular diseases, thereby facilitating timely interventions that help prevent complications. By providing personalized treatment plans based on data collected from wearable devices, mobile apps, and remote monitoring systems, digital therapeutics not only improve patient outcomes but also reduce healthcare costs by minimizing hospital visits and readmissions.

The COVID-19 pandemic further accelerated the adoption of digital health solutions, including digital therapeutics. With the increased reliance on telemedicine and remote healthcare services during lockdowns and social distancing measures, healthcare providers and patients became more accustomed to using digital platforms for treatment and monitoring. This shift towards digital health has had lasting effects, as many patients and clinicians have recognized the convenience, effectiveness, and cost-efficiency of digital therapeutics. This transition is expected to continue, with more healthcare systems across Europe integrating digital therapeutics into routine care practices.

Germany is leading the market in Europe, thanks to its progressive approach to digital health. The country’s introduction of the Digital Healthcare Act (DVG) has been a major catalyst for the growth of digital therapeutics in the region. The DVG allows digital health applications that meet certain regulatory standards to be reimbursed by statutory health insurance, facilitating broader access for patients. Other European countries, such as the United Kingdom, France, and Spain, are also embracing digital therapeutics, but regulatory frameworks and reimbursement systems are still evolving in these nations. As more countries establish clearer reimbursement pathways and regulatory guidelines for digital therapeutics, market penetration is expected to increase across the continent.

Another contributing factor to the growth of the European digital therapeutics market is the rising demand for remote patient monitoring (RPM) solutions. With advancements in mobile health technologies, wearable devices, and connected health systems, remote monitoring has become more accessible to both patients and healthcare providers. DTx solutions that incorporate remote monitoring features allow patients to track their health status in real-time, leading to more proactive management of chronic conditions. This not only empowers patients to take control of their health but also enables healthcare providers to make data-driven decisions based on continuous health data, improving overall care quality.

Despite the promising growth, the European Digital Therapeutics Market still faces several challenges. Regulatory hurdles remain a significant obstacle, particularly with regard to the approval and reimbursement of digital therapeutics in various countries. While Germany has developed a clear regulatory framework, other nations are still working to establish guidelines for DTx products, which can cause delays in market entry for companies. There is a need for better integration of digital therapeutics into existing healthcare infrastructures. Many healthcare systems across Europe still rely heavily on traditional in-person consultations, and integrating digital therapeutics into these systems requires significant investment in technology infrastructure and training.

Another challenge is patient engagement and adoption. While digital therapeutics can offer significant benefits, convincing patients, especially older populations or those with limited digital literacy, to adopt these solutions can be difficult. Ensuring that digital therapeutics are user-friendly, accessible, and engaging is crucial for driving adoption. Ensuring patient adherence to digital therapeutics regimens remains a challenge, as many patients may struggle with consistently using digital tools for self-management.

 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on " Europe Digital Therapeutics Market”

 

The Europe Digital Therapeutics Market is segmented into product type, application, sales channel, country distribution, and company.

Based on sales channel, the Business-to-Business (B2B) model is currently dominating over the Business-to-Customer (B2C) model. The B2B approach involves digital therapeutics companies partnering with healthcare providers, pharmaceutical companies, insurers, and other organizations within the healthcare ecosystem to offer their solutions. This model is more prevalent in Europe due to the complex nature of healthcare systems, which often require digital therapeutics to be integrated into established infrastructures such as hospitals, clinics, insurance programs, and electronic health records (EHR).

The B2B model is particularly effective in Europe because it leverages the existing healthcare framework, which is highly regulated and requires approval from medical authorities, including health insurance companies and government agencies. By working directly with healthcare providers, digital therapeutics companies can ensure that their products meet regulatory requirements and have access to a larger patient population through institutional endorsement. For example, healthcare providers and insurers may work with DTx companies to offer reimbursed treatment solutions for chronic diseases, ensuring widespread adoption and usage among patients. The B2B model allows for greater integration with other healthcare technologies such as telemedicine platforms, remote monitoring devices, and electronic prescriptions. This integration enhances the functionality and reach of digital therapeutics, as they can be seamlessly incorporated into the overall care management strategy of patients. With healthcare providers and pharmaceutical companies being the primary drivers of treatment protocols in Europe, having digital therapeutics incorporated into established workflows is crucial for adoption.

Based on country, United Kingdom is the second-leading country in the Europe Digital Therapeutics Market, following Germany. The UK’s strong healthcare infrastructure, advanced technological ecosystem, and favorable regulatory environment have facilitated the rapid adoption and growth of digital therapeutics. The UK's healthcare system, primarily driven by the National Health Service (NHS), is highly receptive to innovative solutions that aim to improve patient outcomes, reduce costs, and enhance accessibility to care, making it a key player in the European digital therapeutics landscape. One of the key factors driving the UK’s dominance in the market is its supportive regulatory environment. The UK government has shown strong commitment to digital health, as evidenced by its initiatives such as the NHS Long Term Plan, which aims to integrate digital technologies into mainstream healthcare. This includes the use of digital therapeutics to manage chronic conditions, mental health issues, and other health challenges. The NHS Digital has supported the development and deployment of digital solutions, providing pathways for digital therapeutics to be adopted within the system. In terms of adoption, the UK has seen growing partnerships between digital therapeutics companies and NHS providers, which has enabled these solutions to be integrated into routine care for patients. The UK has a well-established infrastructure for telemedicine and digital health solutions, with increasing investments in digital health startups and collaborations between public and private sectors. These efforts have helped digital therapeutics gain traction among healthcare professionals and patients.

 

Major companies operating in Europe Digital Therapeutics Market are:

  • Mindable Health GmbH
  • Cara Care
  • Kaia Health Software GmbH
  • HealthHero
  • GAIA AG
  • ResMed Germany Inc.
  • Sidekick Health Germany GmbH
  • Ada Health GmbH
  • Flatiron Health GmbH
  • Wellster Healthtech Group GmbH

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The future of the Europe Digital Therapeutics Market is highly optimistic, driven by advancements in technology, increasing adoption of digital health solutions, and a growing focus on personalized care. As the demand for chronic disease management, mental health interventions, and preventive care rises, digital therapeutics will become essential in improving patient outcomes and reducing healthcare costs. Regulatory frameworks, particularly in markets like Germany and the UK, are expected to evolve, streamlining market access and reimbursement processes. This will enable wider integration of digital therapeutics into healthcare systems. Increased collaboration between healthcare providers, insurers, and technology companies will further accelerate market growth. The integration of mobile apps, wearables, and data analytics will drive patient engagement and adherence, positioning digital therapeutics as a key player in Europe’s healthcare landscape”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

Europe Digital Therapeutics Market By Product Type (Software and Devices), By Application (Treatment/Patient Care-Related Applications and Preventive Applications), By Sales Channel (Business-to-Business and Business-to-Customer), By Country, Competition, Forecast and Opportunities, 2020-2030F”, has evaluated the future growth potential of Europe Digital Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Europe Digital Therapeutics Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com

Relevant Reports

Europe Digital Therapeutics Market By Product Type (Software and Devices), By Application (Treatment/Patient Care-Related Applications and Preventive Applications), By Sales Channel (Business-to-Business and Business-to-Customer), By Country, Competition, Forecast and Opportunities, 2020-2030F

Healthcare | Jan, 2025

Increasing demand for personalized healthcare solutions and advancements in technology are factors driving the Europe Digital Therapeutics Market in the forecast period 2026-2030.

Relevant News